195 related articles for article (PubMed ID: 10600008)
41. Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.
Moldenhauer G; Henne C; Karhausen J; Möller P
Immunology; 1999 Mar; 96(3):473-84. PubMed ID: 10233730
[TBL] [Abstract][Full Text] [Related]
42. A novel family of human leukocyte antigen class II receptors may have its origin in archaic human species.
Temme S; Zacharias M; Neumann J; Wohlfromm S; König A; Temme N; Springer S; Trowsdale J; Koch N
J Biol Chem; 2014 Jan; 289(2):639-53. PubMed ID: 24214983
[TBL] [Abstract][Full Text] [Related]
43. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
[TBL] [Abstract][Full Text] [Related]
44. Isoforms of the invariant chain regulate transport of MHC class II molecules to antigen processing compartments.
Warmerdam PA; Long EO; Roche PA
J Cell Biol; 1996 Apr; 133(2):281-91. PubMed ID: 8609162
[TBL] [Abstract][Full Text] [Related]
45. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent.
Stebbins CC; Loss GE; Elias CG; Chervonsky A; Sant AJ
J Exp Med; 1995 Jan; 181(1):223-34. PubMed ID: 7807005
[TBL] [Abstract][Full Text] [Related]
46. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
Muczynski KA; Anderson SK; Pious D
J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
[TBL] [Abstract][Full Text] [Related]
47. Human germinal center B cells differ from naive and memory B cells by their aggregated MHC class II-rich compartments lacking HLA-DO.
Chalouni C; Banchereau J; Vogt AB; Pascual V; Davoust J
Int Immunol; 2003 Apr; 15(4):457-66. PubMed ID: 12663675
[TBL] [Abstract][Full Text] [Related]
48. Trafficking of major histocompatibility complex class II molecules through intracellular compartments containing HLA-DM.
Robbins NF; Hammond C; Denzin LK; Pan M; Cresswell P
Hum Immunol; 1996 Jan; 45(1):13-23. PubMed ID: 8655355
[TBL] [Abstract][Full Text] [Related]
49. Decreased endosomal delivery of major histocompatibility complex class II-invariant chain complexes in dynamin-deficient cells.
Wang K; Peterson PA; Karlsson L
J Biol Chem; 1997 Jul; 272(27):17055-60. PubMed ID: 9202021
[TBL] [Abstract][Full Text] [Related]
50. Constitutive intracellular expression of human leukocyte antigen (HLA)-DO and HLA-DR but not HLA-DM in trophoblast cells.
Ranella A; Vassiliadis S; Mastora C; Valentina M; Dionyssopoulou E; Athanassakis I
Hum Immunol; 2005 Jan; 66(1):43-55. PubMed ID: 15620461
[TBL] [Abstract][Full Text] [Related]
51. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
52. Spatial separation of HLA-DM/HLA-DR interactions within MIIC and phagosome-induced immune escape.
Zwart W; Griekspoor A; Kuijl C; Marsman M; van Rheenen J; Janssen H; Calafat J; van Ham M; Janssen L; van Lith M; Jalink K; Neefjes J
Immunity; 2005 Feb; 22(2):221-33. PubMed ID: 15723810
[TBL] [Abstract][Full Text] [Related]
53. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH.
Ullrich HJ; Döring K; Grüneberg U; Jähnig F; Trowsdale J; van Ham SM
Proc Natl Acad Sci U S A; 1997 Nov; 94(24):13163-8. PubMed ID: 9371817
[TBL] [Abstract][Full Text] [Related]
54. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
Hitzel C; van Endert P; Koch N
J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
[TBL] [Abstract][Full Text] [Related]
55. Stable surface expression of invariant chain prevents peptide presentation by HLA-DR.
Roche PA; Teletski CL; Karp DR; Pinet V; Bakke O; Long EO
EMBO J; 1992 Aug; 11(8):2841-7. PubMed ID: 1639058
[TBL] [Abstract][Full Text] [Related]
56. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
[TBL] [Abstract][Full Text] [Related]
57. DR/CLIP (class II-associated invariant chain peptides) and DR/peptide complexes colocalize in prelysosomes in human B lymphoblastoid cells.
Stang E; Guerra CB; Amaya M; Paterson Y; Bakke O; Mellins ED
J Immunol; 1998 May; 160(10):4696-707. PubMed ID: 9590215
[TBL] [Abstract][Full Text] [Related]
58. HLA-DM is expressed on the cell surface and colocalizes with HLA-DR and invariant chain in human Langerhans cells.
Andersson T; Patwardhan A; Emilson A; Carlsson K; Scheynius A
Arch Dermatol Res; 1998 Dec; 290(12):674-80. PubMed ID: 9879837
[TBL] [Abstract][Full Text] [Related]
59. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
[TBL] [Abstract][Full Text] [Related]
60. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
Khalil H; Brunet A; Thibodeau J
J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]